Peplens

Cagrilintide

Limited human data

Investigational long-acting amylin (and calcitonin) receptor agonist peptide · Also known as AM833, long-acting amylin analogue, component of CagriSema

Overview

Cagrilintide is an investigational once-weekly peptide that acts as a long-acting analog of the hormone amylin, promoting satiety and slowed gastric emptying through amylin and calcitonin receptors. It is most studied in combination with semaglutide as the fixed-dose product CagriSema, where co-administration produced greater weight loss than either component alone in published Phase 2 work. The human evidence base is meaningful but still incomplete: as of 2026, Novo Nordisk has reported Phase 3 (REDEFINE) results and filed for FDA approval of CagriSema, but cagrilintide is NOT yet FDA-approved as a stand-alone agent or in combination. It is a true peptide.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

  • Weight loss / obesity, usually combined with semaglutide as CagriSema (investigational; Phase 2/3 human data, not yet FDA-approved)
  • Type 2 diabetes adjunct in combination with semaglutide (investigational; Phase 2 human data)
  • Appetite/satiety modulation as an amylin-pathway agent (mechanistic claim; human monotherapy evidence limited)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

  • Smart scale — weight and body-fat % trend
  • InBody/DEXA — skeletal muscle mass vs. fat mass during weight loss
  • Labs — HbA1c and fasting glucose if used in a diabetes context
  • MyFitnessPal — calories and protein g/kg, given strong appetite effects
  • Subjective — daily appetite, nausea, and GI tolerability check-ins

Sources & References

  1. [1]Co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial (The Lancet, 2023)
  2. [2]Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (NEJM)
  3. [3]Novo Nordisk files for FDA approval of CagriSema — PR Newswire

Quick Reference

Class
Investigational long-acting amylin (and calcitonin) receptor agonist peptide
Evidence Level
Limited human data
Reported Uses
3 listed
Tracking Metrics
5 suggested
Citations
3 sources

Safety & legal notes

NOT FDA-approved; investigational and, as of 2026, under FDA review as part of the CagriSema combination. In trials the most common adverse events were mild-to-moderate gastrointestinal symptoms. Amylin analogs are peptide hormones; while GLP-1 agonists are only monitored (not banned) by WADA, athletes should not assume the same for every metabolic peptide and should verify current status. Gray-market 'research only' cagrilintide is not quality-controlled. Long-term human safety is not established. Consult a licensed clinician.

Track your protocol in Peplens

Connect your InBody, Whoop, smart scale, and nutrition data. See your Overlay — all metrics, one clear read.

Get started free →
← All entries